VOR – vor biopharma inc. (US:NASDAQ)
Stock Stats
News
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Form 4 Vor Biopharma Inc. For: Dec 05 Filed by: Mahatme Sandesh
Form 4 Vor Biopharma Inc. For: Dec 05 Filed by: Zuraw Qing Che
Form 4 Vor Biopharma Inc. For: Dec 05 Filed by: Kress Jean-Paul
Form 8-K Vor Biopharma Inc. For: Dec 05
Form 424B3 Vor Biopharma Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.